Novartis' Phase III Results on Secukinumab Published - Analyst Blog

By
A A A

Novartis ( NVS ) announced that results from two pivotal phase III studies on pipeline candidate, secukinumab (AIN457), were published in the N ew England Journal of Medicine .

Novartis is evaluating secukinumab for the treatment of psoriasis. The results from the studies, ERASURE and FIXTURE, showed that secukinumab met all primary and key secondary endpoints at week 12 and showed superiority to Amgen's ( AMGN ) Enbrel in improving moderate-to-severe plaque psoriasis symptoms in the FIXTURE study, and was superior to placebo in both studies.

In addition, patients treated with secukinumab also reported improvements in itching, pain and scaling, compared to placebo at Week 12, in the ERASURE study.

Moreover, secukinumab showed an acceptable safety profile in both the studies which was consistent with phase II studies. We note that Novartis submitted secukinumab to regulatory bodies both in the U.S. and EU in 2013 for the treatment of psoriasis.

Meanwhile, Novartis is also evaluating secukinumab for arthritic conditions such as psoriatic arthritis, ankylosing spondylitis and rheumatoid arthritis.

The successful development and commercialization of secukinumab for the treatment of psoriasis will further strengthen Novartis' dermatology portfolio. Novartis already has Xolair in its dermatology portfolio which is approved for the treatment of refractory chronic spontaneous urticaria (CSU) in the EU and is known as refractory chronic idiopathic urticaria (CIU) in the U.S.

Novartis, a large cap pharma, currently carries a Zacks Rank#3 (Hold). Some better-ranked large cap pharmas include AbbVie, Inc . ( ABBV ) and Johnson & Johnson ( JNJ ). Both the stocks carry a Zacks Rank #2 (Buy).


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

AMGEN INC (AMGN): Free Stock Analysis Report

NOVARTIS AG-ADR (NVS): Free Stock Analysis Report

JOHNSON & JOHNS (JNJ): Free Stock Analysis Report

ABBVIE INC (ABBV): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: CSU , CIU , AMGN , NVS , JNJ

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com